733aa64f-0d61-4f6a-8353-0299d4678704
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.300
- PROTEIN_SECRETION+0.200
- ADIPOGENESIS+0.100
- ANDROGEN_RESPONSE+0.100
- BILE_ACID_METABOLISM+0.100
- E2F_TARGETS+0.100
- FATTY_ACID_METABOLISM+0.100
- NOTCH_SIGNALING+0.100
- OXIDATIVE_PHOSPHORYLATION+0.100
- UV_RESPONSE_DN+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- MYC_TARGETS_V2-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- APOPTOSIS-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- COMPLEMENT-0.300
- HYPOXIA-0.300
- IL2_STAT5_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 60e8eebe-9770-4db0-9892-d1100114c923 | — | — | 0.829 |
| 2 | 4ca7e773-3858-4ece-b78a-c576b20a5cf3 | — | — | 0.789 |
| 3 | 47b69c13-020e-43d0-ac3c-686acf4932a2 | — | — | 0.772 |
| 4 | 204241b7-1e28-43f8-a681-f872b52fa3f8 | — | — | 0.771 |
| 5 | f8676f25-4b49-44b3-b953-c457c3be5a3b | — | — | 0.767 |
| 6 | SRR8518182 | — | C | 0.760 |
| 7 | BS_G7AGNB5G | low-grade glioma | — | 0.752 |
| 8 | TCGA-K4-A6MB-01A-11R-A31N-07 | — | — | 0.750 |
| 9 | aMVAC.P_016_TURBT_S236 | — | — | 0.747 |
| 10 | TCGA-97-7937-01A-11R-2170-07 | — | cohortA1 | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |